CollPlant Biotechnologies LtdCLGNEarnings & Financial Report
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
CLGN Q2 FY2023 Key Financial Metrics
Revenue
$10.2M
Gross Profit
$9.6M
Operating Profit
$5.7M
Net Profit
$5.8M
Gross Margin
94.0%
Operating Margin
55.7%
Net Margin
56.6%
YoY Growth
15330.3%
EPS
$0.49
CollPlant Biotechnologies Ltd Q2 FY2023 Financial Summary
CollPlant Biotechnologies Ltd reported revenue of $10.2M (up 15330.3% YoY) for Q2 FY2023, with a net profit of $5.8M (up 234.5% YoY) (56.6% margin). Cost of goods sold was $615.0K, operating expenses totaled $3.9M.
Key Financial Metrics
| Total Revenue | $10.2M |
|---|---|
| Net Profit | $5.8M |
| Gross Margin | 94.0% |
| Operating Margin | 55.7% |
| Report Period | Q2 FY2023 |
Income Statement
| Q2 2023 | |
|---|---|
| Revenue | $10.2M |
| YoY Growth | 15330.3% |
Balance Sheet
| Q2 2023 | |
|---|---|
| Assets | $41.6M |
| Liabilities | $5.5M |
| Equity | $36.0M |